Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane, M Winderlich, M Dirnberger-Hertweck, R Korolkiewicz, K A Blum, W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane, M Winderlich, M Dirnberger-Hertweck, R Korolkiewicz, K A Blum

Abstract

Background: This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin's lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells.

Patients and methods: Patients aged ≥18 years, with R-R NHL progressing after ≥1 prior rituximab-containing regimen were enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL and mantle cell lymphoma (MCL). Treatment was MOR208, 12 mg/kg intravenously, weekly, for 8 weeks. Patients with at least stable disease could continue treatment for an additional 4 weeks. Those with a partial or complete response after 12 weeks could receive extended MOR208 treatment (12 mg/kg, either monthly or every second week) until progression. The primary end point was overall response rate.

Results: Ninety-two patients were enrolled: DLBCL (n = 35), FL (n = 34), other iNHL (n = 11) and MCL (n = 12). Responses were observed in DLBCL, FL and other iNHL cohorts (26%, 29% and 27%, respectively). They lasted ≥12 months in 5/9 responding patients with DLBCL, 4/9 with FL and 2/3 with other iNHL. Responses in nine patients are ongoing (>26 months in five instances). Patients with rituximab refractory disease showed a similar response rate and progression-free survival time to patients with non-refractory disease. The most common adverse events (any grade) were infusion-related reactions (12%) and neutropenia (12%). One patient experienced a grade 4 infusion-related reaction and eight patients (9%) experienced grade 3/4 neutropenia. No treatment-related deaths were reported.

Conclusions: MOR208 monotherapy demonstrated promising clinical activity in patients with R-R DLBCL and R-R FL, including in patients with rituximab refractory tumors. These efficacy data and the favorable safety profile support further investigation of MOR208 in phase II/III combination therapy trials in R-R DLBCL.

Clinicaltrials.gov number: NCT01685008.

Figures

Figure 1.
Figure 1.
Time to and duration of response. aOne patient with stable disease had a late response (PR) after 17 months in follow-up. Outcome for this patient is not shown in the figure. CR, complete response; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin’s lymphoma; PR, partial response.

References

    1. Wang K, Wei G, Liu D.. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1(1): 36..
    1. Fujimoto M, Poe JC, Inaoki M, Tedder TF.. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 1998; 10: 267–277.
    1. Seda V, Mraz M.. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 2015; 94(3): 193–205.
    1. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS.. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 2006; 35(1): 93–114.
    1. Schuurman HJ, Huppes W, Verdonck LF. et al. Immunophenotyping of non-Hodgkin’s lymphoma. Correlation with relapse-free survival. Am J Pathol 1988; 131: 102–111.
    1. Hiraga J, Tomita A, Sugimoto T. et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009; 113(20): 4885–4893.
    1. Kamburova EG, Koenen HJ, Joosten I, Hilbrands LB.. CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al. Arthritis Rheum 2013; 65(4): 1130–1131.
    1. Awan FT, Lapalombella R, Trotta R. et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115(6): 1204–1213.
    1. Horton HM, Bernett MJ, Pong E. et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68(19): 8049–8057.
    1. Woyach JA, Awan F, Flinn IW. et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood 2014; 124(24): 3553–3560.
    1. Cheson BD, Pfistner B, Juweid ME. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579–586.
    1. Ribrag V, Dupuis J, Tilly H. et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014; 20(1): 213–220.
    1. Goebeler ME, Knop S, Viardot A. et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 2016; 34(10): 1104–1111.
    1. Neelapu SS, Locke FL, Bartlett NL. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377(26): 2531–2544.
    1. Schuster S, Bishop M, Tam C. et al. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) – an interim analysis. Hematol Oncol 2017; 35: 27.
    1. Abramson J, Palomba M, Gordon L. et al. CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). J Clin Oncol 2017; 35(Suppl 15): Abstr 7513.
    1. Schuster SJ, Svoboda J, Chong EA. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017; 377(26): 2545–2554.
    1. Winderlich M, Ness D, Steidl S, Endell J.. Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma. J Clin Oncol 2012; 30(Suppl 15): Abstr 6574.
    1. Salles G, Duell J, González-Barca E. et al. Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-MIND. Blood 2017; 130(Suppl 1): Abstr 4123.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅